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Liposomal anesthetic gel for pain 
control during periodontal therapy in 
adults: a placebo-controlled RCT
Periodontal therapy usually requires local anesthesia. If effective, a non-
invasive, liposomal anesthetic gel could increase the levels of acceptance of 
patients in relation to periodontal therapy. Objective: This study investigated 
the efficacy of liposomal anesthetic gel for pain control during periodontal 
therapy. Methodology: Forty volunteers with moderate to severe chronic 
periodontitis were recruited, of which at least three sextants required 
periodontal therapy. At least one of the selected teeth had one site with a 
probing depth of ≥4 mm. The volunteers received the following three gels: 
a placebo, lidocaine/prilocaine (Oraqix®), or a liposomal lidocaine/prilocaine, 
which were applied to different sextants. Pain frequency was registered 
during treatment and the volunteers received a digital counter to register 
any painful or uncomfortable experiences. At the end of each session, the 
volunteers indicated their pain intensity using rating scales (NRS-101 and 
VRS-4). The volunteers had their hemodynamic parameters measured by a 
non-invasive digital monitor. Results: Pain frequency/intensity did not show 
statistical difference between intervention groups. The tested gels did not 
interfere with the hemodynamic indices. Dental anxiety, suppuration and 
probing depth could influence pain during periodontal therapy. Conclusion: 
Our results suggest limited indications for the use of non-invasive anesthesia 
when used for scaling and root planing. Intra-pocket anesthetic gel could 
be a good option for anxious patients, or those who have a fear of needles. 
Keywords: Anesthetics. Periodontal debridement. Pain management. 
Dental scaling. Clinical trial.
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Introduction
Severe periodontitis is the sixth most prevalent 
condition worldwide, affecting 11% of the global 
population (743 million people aged 15-99 worldwide). 
It has remained static on a global scale during the last 
two decades. The age-standardized incidence of the 
disease did not change from 1990-2010 (696 and 701 
cases per 100,000 person-years, respectively). These 
prevalence and incidence rates were similar for males 
and females, and increased with age, with a steep 
increase among individuals aged from 30 to 40 years 
old, remaining stable thereafter.1
Periodontal therapy usually involves supra and/
or subgingival scaling and root planing (SRP),2 which 
can be performed using periodontal curettes or sonic 
and ultrasonic instruments. The prevalence of pain 
and discomfort during SRP is variable, but studies 
report around 15% to 33% of patients describing it 
as a significantly painful experience.3,4 Reasons for 
this include tissue trauma caused by instrumentation, 
dentin hypersensitivity,2 and the unpleasant noise and 
sensation produced by periodontal curettes and sonic 
or ultrasonic instruments when they come into contact 
with the tooth structure.5,6 
The usual technique to control pain and discomfort 
during SRP is applying local anesthetic injections 
(nerve block or infiltration anesthesia).7-9 However, 
patients often report a fear of needles, and complain 
about pain and discomfort caused by their insertion 
and prolonged numbness in the surrounding soft 
tissues.7,8,10,11 These factors can lead patients to delay, 
or even avoid, periodontal therapy.7,12
New anesthetic formulations have been developed 
to improve treatment conditions and ameliorate the 
patients’ level of acceptance of dental procedures.11,13 
Oraqix® (25 mg/g  lidocaine and 25 mg/g prilocaine) 
was developed with the addition of a thermosetting 
agent.9,14,15 The onset of anesthesia has been shown 
to range from 30 seconds to 2 minutes after its 
application, and some studies have demonstrated that 
it is the best non-invasive anesthesia option for SRP 
thus far.8,11,14,16 Another alternative is the combination 
of local anesthetics with liposomal formulations, which 
can increase the duration of anesthesia, decrease 
central nervous and cardiac toxicity, and decrease 
circulating plasma levels.17-19 Studies have shown 
significant skin and oral mucosa anesthesia using 
liposome-encapsulated anesthetics;20-22 but until now, 
there has been no evaluation of their efficacy in the 
periodontal pocket, especially during SRP.
The aim of this study was to compare the effects 
of a liposomal, lidocaine/prilocaine, thermosetting 
anesthetic gel for pain control during scaling and root 
planing (anti-infective periodontal therapy) compared 
to Oraqix® (positive control) gel, and a placebo gel 
(negative control). Our primary outcome was the 
frequency/intensity of pain, obtained by using a digital 
counter to register any painful experience; a numerical 
rating scale (NRS-101) and a verbal rating scale 
(VRS-4) were used. The secondary outcomes were 
hemodynamic parameters (systolic blood pressure, 
diastolic blood pressure, heart rate and oxygen 
saturation). The null hypothesis was that there would 
be no difference between intervention groups (placebo 
and anesthetic gels) in relation to pain control during 
scaling and root planing.
Methodology
Study population
A flowchart of the overall study design is shown 
in Figure 1. After approval by the Joint Research and 
Ethics Committee (CEP – 78.2009.15036.09; Clinical 
Trials Registry: Primary Id Number: RBR-934sys), we 
selected forty volunteers for this randomized, double-
blind, cross-over, placebo-controlled clinical trial. The 
volunteers were individually made aware of the study 
protocol and the aims of the study prior to enrollment. 
The study was performed according to the guidelines 
of the Helsinki Declaration.
Sample size
Sample size calculation was based on pain intensity 
(primary outcome) using visual analogue scale (VAS) 
data that was previously published in a study which 
reported the effects of intra-pocket lidocaine and 
prilocaine gel (2.5% each) in SRP.13 If the sample size 
in each intervention group was 38 (1:1:1 allocation 
ratio), a two-sided test would have 80% power at an 
effect size of 0.65, and 0.05 significance level in order 
to detect a minimum, clinically important difference of 
15 units in the VAS. The sample size was increased to 
40 volunteers per group to account for the potential 
loss of volunteers during the study. Sample size was 
calculated using a specific software (G*Power Version 
3.1.9.2; http://www.gpower.hhu.de).
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Randomization and allocation concealment
Block randomization was used to allocate 
three sextants of each volunteer in relation to the 
interventions (placebo, Oraqix® and Liposomal), using 
a computer program (Microsoft® Excel for Mac version 
10.4, 2011). The random allocation sequence was 
printed and sealed in envelopes with the volunteer’s 
number on the outside. This procedure was performed 
and monitored by one researcher (FAS).
Inclusion and exclusion criteria
The volunteers had to be aged 18 or older; they 
needed anti-infective periodontal therapy and had to 
have at least three sextants with a minimum of two 
vital teeth requiring scaling and root planing. They also 
needed to have sought dental care at the University 
Dental Clinic. At least two sites per sextant with a 
probing depth of 4 mm or more and clinical signs of 
periodontal disease (presence of supra/subgingival 
calculus and/or dental biofilm, as well as bleeding/
suppuration on probing) were required for them to be 
included in this study. 
The exclusion criteria were: individuals undergoing 
periodontal maintenance; any allergic reaction to 
amide anesthetic; consumption of any analgesic or 
anti-inflammatory drugs in the 12 hours prior to 
treatment; individuals with a history of alcoholism; 
smokers; pregnant or lactating women; individuals 
Figure 1- Flowchart of subjects throughout the stages of the study. At the end of the clinical trial, all untreated sextants received periodontal 
treatment
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with any non-controlled systemic disorder such as 
cardiac, neurological, kidney, liver, hematological or 
psychological alterations; individuals with presence 
of ulcerative lesions, abscesses or acute infections; 
individuals with the need for dental extraction 
in the selected sextants; individuals with dentin 
hypersensitivity; and individuals with endodontic 
treatment or any other alteration that could compromise 
the measurement of data. 
Evaluation of clinical parameters 
The data regarding probing depth, width of 
keratinized mucosa, bleeding on probing (presence 
or absence), dental plaque (presence or absence) 
and suppuration (presence or absence) were obtained 
at baseline. Measurements were performed using a 
standardized UNC periodontal probe (Hu-Friedy®, Rio 
de Janeiro, RJ, Brazil). The volunteers were also asked 
to complete Corah’s Dental Anxiety Scale (DAS) before 
the first treatment session. 
Anesthetic procedures and treatment
Three different gels were used in this study: 
a lidocaine/prilocaine thermosetting gel (Oraqix®, 
Dentsply, York, PA, United States), which served 
as positive control, a liposomal lidocaine/prilocaine 
thermosetting gel (granulated lecithin (6.6 g); 
isopropyl palmitate (7.6 mL); sorbic acid or benzoic 
acid (0.12 g); poloxamer 407 (6.78 g); poloxamer 188 
(2.40 g); potassium sorbate or sodium benzoate (0.1 
g); purified water (30 mL on the first day/10 mL on the 
second day); ethanol (2.5 mL); hydrochloric acid (0.1 
mL); lidocaine (25 mg/g) and prilocaine (25 mg/g)). 
The large multilamellar liposomes were obtained 
by the thin film hydration method. Subsequently, 
lecithin and isopropyl palmitate were dissolved in 
chloroform. The lipid mixture was then deposited as 
a thin film into a round-bottomed flask using a rotary 
evaporator after full removal of the chloroform under 
vacuuming at 40oC in a temperature-controlled water 
bath for a period of 2 hours to ensure the absence 
of solvent residue. The films were suspended in 20 
mmol/L HEPES buffer (7.4 pH, containing 154 mmol/L 
NaCl), and multilamellar vesicles were obtained after 
vortexing at room temperature (5 min, 25oC). Large 
multilamellar vesicles were prepared by extruding (20 
cycles) these vesicles within 400 nm-membrane filters 
at 25°C using an extruder device (Lipex Biomembranes 
Inc. Vancouver, BC, Canada). The loaded liposomes 
containing lidocaine base (2.5%) and prilocaine base 
(2.5%) were prepared by adding these anesthetics 
directly to the previously obtained liposomes after 
extrusion at the final concentration of 5%. The 
loaded liposomes formed appear as concentric and 
non-concentric multilamellar vesicles by TEM with 
327.5±17.5 nm and PDI of 0.21±0.08 by dynamic 
light scattering. The mean encapsulation efficiency was 
54.9±15.2% by HPLC/DAD. The unloaded and loaded 
formulations were stable at 4oC for 3 months. The 
thermosetting gel was prepared using the poloxamer 
solutions (407 and 188). These polymers were 
dispersed in purified water via manual stirring. The 
solutions were then stored in a refrigerator at 4ºC for 
at least 12 h to ensure complete solvation. Liposomal 
anesthetics were then added to the gel with manual 
stirring until a homogeneous dispersion was obtained. 
The placebo gel had the same composition as the 
liposomal gel, but without the anesthetic bases, and 
served as negative control. All the selected volunteers 
received the gels on different teeth, from different 
sextants, using a cross-over design and with one-
week intervals between each appointment to avoid 
cross-over contamination (spill-over effect).23 The 
anesthetic agents were stored in identical syringes 
and were identified only by letters. The anesthesia was 
administered by a blinded operator (SCSP) according 
to a randomization process, who also performed the 
periodontal therapy procedures. The sextants were 
isolated with cotton rolls and the anesthetic gel was 
placed inside the periodontal pocket for about one 
minute before SRP. A second examiner (GSM) was 
responsible for collecting the data of each volunteer. 
SRP was performed using Gracey and McCall curettes 
(Millennium®, Golgran, Rio de Janeiro, RJ, Brazil). 
The volunteers could ask for rescue anesthesia (3% 
prilocaine with 0.03 IU/mL felypressin injection, 
Citanest®, Dentsply, Catanduva, SP, Brazil) if they were 
still feeling pain after two applications of gel. 
Pain evaluation
Pain frequency was obtained during the SRP 
procedures; the volunteers received a digital counter 
to register any painful or uncomfortable experience. At 
the end of each session, the volunteers were asked to 
indicate pain intensity using the numerical rating scale 
(NRS-101), and discomfort using a four-point verbal 
rating scale (VRS-4) (1=none; 2=mild; 3=moderate; 
4=severe). If rescue anesthesia was required, the pain 
and discomfort scores were obtained before it was 
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administered. The volunteers were also asked to rate 
how unpleasant the taste of the anesthetic agent was 
(“acceptable”; “slightly unpleasant”; “very unpleasant” 
and “I would not like to receive it again”). 
Assessment of hemodynamic parameters 
During the treatments, the volunteers had their 
hemodynamic parameters (systolic blood pressure, 
diastolic blood pressure, heart rate and oxygen 
saturation) measured by a non-invasive digital 
monitor (INMAX® Monitor Multiparamétrico, Instramed 
Indústria Médico Hospitalar Ltda, Porto Alegre, RS, 
Brazil). 
Statistical analysis
The data regarding pain frequency and the NRS-
101 and VRS-4 pain scales did not show normal 
distribution and homogeneity of variance. The 
volunteers had different sextants treated with different 
numbers of teeth in each one, so a paired test would 
not be suitable; the Kruskal-Wallis non-parametric 
test was used to determine the differences between 
intervention groups.
The clinical parameters, such as distribution of 
sextants, probing depth (≤3 mm, 4-5 mm or 6 mm) 
and keratinized mucosa (≤2 mm or >2 mm), were 
compared using the chi-square test (χ2). The mean 
number of teeth, dental plaque, bleeding on probing, 
suppuration, probing depth and width of keratinized 
mucosa were analyzed by the Kruskal-Wallis test (non-
normal distribution). 
A univariate regression analysis, with random 
intercept, was performed to explore the relationship 
between the primary outcome of interest (pain 
frequency/intensity) and the various risk factors24, 
comprising the following levels: site level (dental 
plaque, bleeding on probing, suppuration probing 
depth and width of keratinized mucosa), sextant level 
(position and number of teeth) and subject level (age, 
gender, periodontal diagnosis and dental anxiety). 
The hemodynamic parameters (systolic and 
diastolic blood pressure, heart rate and oxygen 
saturation) were analyzed at baseline, during and 
after treatment by repeated measures ANOVA and 
the paired t-test.
The data obtained via trans-operative and post-
operative scaling and root planing in the three 
intervention groups, such as volume of anesthetic gel 
applied, number of applications, need for additional 
(rescue) anesthesia, time required for periodontal 
therapy (per sextant), difficulties during treatment, 
post-operative discomfort due to treatment and 
the volunteers’ perceptions of the gel’s flavor were 
analyzed by the ANOVA, Kruskal-Wallis and χ2 tests, 
according to the type and distribution of the variables.
The tests were considered statistically significant 
when p<0.05 (IBM® SPSS® 21.0 Statistics, IBM Corp., 
Armonk, NY, USA).
Results
Of the forty randomized volunteers, thirty-eight 
managed to conclude the study and two did not return 
for the second appointment. Figure 1 shows the study 
flowchart. The sample comprised 23 (60%) females 
and 15 (40%) males, aged from 26 to 73 years old 
(mean age: 43.6±11.2 years old) and diagnosed 
with localized periodontitis (45%) or generalized 
periodontitis (55%). 
Figure 2- Pain during/after scaling and root planing in periodontal therapy. (A) Median with interquartile range (lines) of pain frequency 
(no significant findings, p=0.316). (B) Median with interquartile range (lines) of NRS-101 (no significant findings,p =0.250). The dots 
correspond to each volunteer. (C). VRS-4 scores: Percentage of subjects in the Placebo, Oraqix®; and Liposomal groups who reported no, 
mild, moderate, and severe pain (no significant findings, p=0.231). Kruskal-Wallis test
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Figure 2 shows the pain felt during/after SRP by the 
different groups using pain frequency and the numerical 
rating scale (NRS-101) and verbal rating scale (VRS-4) 
values. The number of volunteers reporting no pain 
frequency during SRP was 19 (50%) for the placebo; 
25 (66%) for Oraqix®, and 21 (55%) for liposomal 
gel. No statistically significant differences were found 
between intervention groups (p>0.05). The mean ±SD 
(95% CI) values for NRS-101 were 31.6±31.9 (21.1 
– 42.1) for the placebo; 20.5±23.5 (12.8 – 28.2) for 
Oraqix®; and 25.0±29.6 (15.3 – 34.7) for liposomal 
gel. The number of volunteers reporting no pain (pain 
Parameters Intervention Groups p
Placebo Oraqix® Liposomal value
Sextants (%)* 0.834ns
Upper Right 6 (16) 5 (13) 9 (24)
Upper Anterior 5 (13) 8 (21) 4 (11)
Upper Left 10 (26) 6 (16) 6 (16)
Lower Left 5 (13) 4 (11) 3 (8)
Lower Anterior 5 (13) 6 (16) 8 (21)
Lower Right 7 (18) 9 (24) 8 (21)
Number of 
teeth†
121 121 114 0.580ns
Mean±SD 3.2±0.9 3.2±1.0 3.0±1.0
Median (IqR) 3.0 (2.0 – 4.0) 3.0 (2.8 – 4.0) 3.0 (2.0 – 4.0)
DP (%)† 0.777ns
Mean ±SD 65.7±32.1 72.4±25.3 69.3±31.0
Median (IqR) 75.0 (37.5 – 100) 75.0 (50.0 – 93.8) 79.2 (50.0–100)
BoP (%)† 0.235ns
Mean ±SD 89.8±18.2 82.0±26.0 89.4±15.1




Mean ±SD 13.9±17.6a 0.0±0.0b 10.8±19.0a
Median (IqR) 10.4 (0.0 – 18.8) 0.0 (0.0 -0.0) 0.0 (0.0 – 12.5)
PD (mm)† 0.288ns
Mean ±SD 3.5±1.4 3.6±1.4 3.5±1.3
Median (IqR) 3.0 (3.0 – 4.0) 3.0 (3.0 -4.0) 3.0 (3.0 – 4.0)
Sites (%) with 
PD per sextant*
≤3 mm 4-5 mm ≥6 mm ≤3 mm 4-5 mm ≥6 mm ≤3 mm 4-5 mm ≥6 mm 0.246ns
All sextants 422 (58)  250 
(34)
 54 (7)  394 (54)  265 
(37)
 67 (9)  386 (56)  254 
(37)
 44 (6)
Upper Right 68 (57)  48 (40)  4 (3)  60 (56)  35 (32)  13 (12)  111 (64)  58 (33)  5 (3)
Upper Anterior 73 (61)  39 (32)  8 (7)  98 (51)  73 (38)  21 (11)  37 (51)  29 (40)  6 (8)
Upper Left 87 (50)  60 (34)  27 (16)  66 (61)  39 (36)  3 (3)  57 (56)  35 (34)  10 (10)
Lower Left 67 (74)  22 (24)  1 (1)  36 (50)  34 (47)  2 (3)  30 (71)  12 (29)  0 (0)
Lower Anterior 60 (56)  39 (36)  9 (8)  68 (60)  28 (25)  18 (16)  78 (50)  66 (42)  12 (8)
Lower Right 67 (59)  42 (37)  5 (4)  66 (50)  56 (42)  10 (8)  73 (53)  54 (39)  11 (8)
Width of KM 
(mm)†
0.089ns
Mean ±SD 3.8±1.5 3.7±1.6 3.9±1.7
Median (IqR) 4.0 (3.0 – 5.0) 4.0 (2.0 – 5.0) 4.0 (3.0 – 5.0)
Site (%) with 
KM*
0.231ns
≤2 mm 108 (21) 131 (25)  123 (24)
>2 mm 411 (79) 391 (75)  387 (76)
*2; †Kruskal-Wallis (different letters indicate significant difference – p<0.0001). ns not statistically significant (p≥0.05); s statistically 
significant (p<0.05); IqR. (Interquartile range)
Table 1- Distribution of sextants, number of teeth and periodontal clinical parameters: Dental plaque (DP); Bleeding on Probing (BoP); 
Suppuration; Probing depth (PD) and width of keratinized mucosa (KM)
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scale=0) using the NRS-101 scale was two (5%) for 
the placebo; six (16%) for Oraqix®; and eight (21%) 
for liposomal gel. Using the VRS-4 scale, no pain 
was observed in 18 (47%), 26 (68%) and 25 (66%) 
volunteers for those who underwent SRP with the 
placebo, Oraqix®, and liposomal gel, respectively. No 
statistical differences were found between intervention 
groups (p<0.05). 
The sextants, number of teeth, and clinical 
parameters (dental plaque, bleeding on probing, 
suppuration, probing depth, and width of keratinized 
mucosa) are shown in Table 1. The intervention groups 
showed statistically significant differences (p<0.0001) 
for suppuration. Sextant position, number of teeth, 
dental plaque, bleeding on probing, probing depth, 
and width of the keratinized mucosa had a similar 
distribution, with no statistically significant differences 
(p>0.05). 
The multilevel regression analysis (Table 2) showed 
statistical significance for the variance at two levels 
(subject and site). Subject-level variance, considering 
all the pain measurements, was responsible for 65% 
of the total outcome variation. Site-level variance was 
associated with 30% of the variation of the results. 
Taking into consideration the subject level covariates, 
the factors of dental anxiety and periodontal diagnosis 
Dependent Variables
Fixed Effects Pain Frequency NRS-101 VRS-4
Estimate (SE) p value Estimate (SE) p value Estimate (SE) p value
Intercept* 0,085 0.848ns 2,367 0.214ns 0,907 0.267ns
(-0.442) (-1.804) (-0.817)
Subject-level covariates
Age 0,005 0.041s -0,015 0.115ns -0,002 0.107ns
(-0.002) (-0.009) (-0.001)
Gender -0,2 0.001s 0,381 0.097ns 0,058 0.051ns
(-0.062) (-0.229) (-0.03)
Periodontal diagnosis 0,319 <0.0001s 0,182 0.336ns 0,252 <0.0001s
(-0.051) (-0.189) (-0.024)
Anxiety 0,024 0.005s 0,084 0.007s 0,008 0.054ns
(-0.008) (-0.031) (-0.004)
Sextant-level covariates
Number of teeth -0,039 0.158ns -0,243 0.017s 0,012 0.672ns
(-0.027) (-0.101) (-0.033)
Position 0,005 0.948ns 0,245 0.522ns -0,006 0.724ns
(-0.072) (-0.35) (-0.013)
Site-level covariates
Dental plaque 0,0225 0.662ns -0,036 0.851ns -0,055 0.027s
(-0.052) (-0.192) (-0.025)
Bleeding on Probing -0,106 0.107ns -0,322 0.187ns -0,092 0.004s
(-0.066) (-0.244) (-0.032)
Suppuration 0,217 0.008s 0,716 0.019s 0,074 0.062ns
(-0.082) (-0.304) (-0.039)
Probing Depth 0,007 0.667s 0,14 0.022s 0,02 0.011s
(-0.016) (-0.061) (-0.008)
Keratinized Mucosa -0,029 0.140ns 0,081 0.267s 0,004 0.652ns
(-0.019) (-0.073) (-0.009)
Random effects
Subject level 0,316 <0.0001s 5,523 <0.0001s 0,106 <0.0001s
(-0.074) (-1.294) (-0.025)
Sextant level 0,054 0.121ns 0,415 0.124ns 0,005 0.124ns
(-0.035) (-0.270) (-0.003)
Site level 0,246 <0.0001s 2,107 <0.0001s 0,036 <0.0001s
(-0.008) (-0.065) (-0.011)
*Formal significance of the intercept coefficient estimate remains trivial in the presence of covariates. ns not statistically significant 
(p≥0.05); s statistically significant (p<0.05)
Table 2- Three-level random intercept model for the outcome variable of pain during scaling and root planing using the restricted maximum 
likelihood estimation (REML)
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(localized or generalized periodontitis) had an influence 
(p<0.05) on the outcome, with at least two methods 
of pain intensity evaluation. The site-level covariates, 
suppuration and probing depth influenced (p<0.05) 
pain intensity on at least two of the measurement 
scales (p<0.05).
Parameters Variables Groups p value*






Sys. BP, mm Hg Baseline 129.7±17.72 129.5±17.98 130.0±21.37 0.967ns
During treatment 130.4±18.03 131.1±18.84 130.2±19.53 0.919ns
After  treatment 130.7±20.40 128.6±15.90 133.2±21.10 0.198ns
p value* 0.821ns 0.314ns 0.326ns - - -
CV of Sys BP (%) 4.79±3.89 4.25±3.27 4.23±3.75 0.692ns
Dia. BP, mm Hg Baseline 85.66±12.97 84.37±10.08 85.37±14.84 0.766ns
During treatment 85.84±11.41 84.26±10.58 86.11±13.15 0.411ns
After  treatment 84.58±13.68 85.37±11.95 86.63±12.60 0.519ns
p value* 0.346ns 0.386ns 0.653ns - - -
CV of Dia BP (%) 5.94±5.84 5.25±4.68 5.56±4.69 0.811ns
HR, beats/min Baseline 93.92±18.63 93.16±17.30 95.58±19.38 0.449ns
During  Treatment 92.55±23.16 93.39±16.70 93.29±24.57 0.925ns
After  treatment 92.37±19.17 92.97±18.56 95.45±19.97 0.180ns
p value* 0.704ns 0.923ns 0.518ns - - -
CV of HR (%) 5.44±4.10 4.13±3.17 5.19±4.79 0.322ns
SpO2, % Baseline 95.26±1.97 95.53±1.67 95.05±3.05 0.331ns
After treatment 95.66±1.76 95.55±1.57 95.26±1.88 0.179ns
p value‡ 0.347ns 0.907ns 0.564ns - - -
CV of SO2 (%) 0.65±0.53 0.72±0.73 0.81±1.61 0.708ns
Sys. BP, systolic blood pressure, Dia. BP, diastolic blood pressure, HR, heart rate, SpO2, oxygen saturation. CV, coefficient of variation
*Repeated measures ANOVA; ‡Paired t test
ns not statistically significant (p≥0.05); s statistically significant (p<0.05)
Table 3- Comparison of mean (±SD) values of hemodynamic parameters
Parameters Intervention Groups p value
Placebo Oraqix® Liposomal
Anesthetic gel volume (mL)*
Mean ±SD 0.54±0.24 0.55±0.29 0.53±0.28 0.754ns
Median (Interquartile range) 0.5 (0.37 – 0.72) 0.5 (0.40 – 0.60) 0.4 (0.30 – 0.62)
Number of applications‡
Mean ±SD 1.61±0.79 1.40±0.64 1.45±0.76 0.396ns
Median (Interquartile range) 1.0 (1.0 – 2.0) 1.0 (1.0 – 2.0) 1.0 (1.0 – 2.0)
Need for additional (rescue) anesthesia (%)† 0.250ns
No 30 (79) 35 (92) 31 (82)
Yes 8 (21) 4 (8) 7 (18)
Time required for scaling and root planing (min)* 0.719ns
Mean ±SD 15.03±6.02 14.13±5.40 14.05±5.94
Median (Interquartile range) 14.0 (10.7 – 19.0) 13.0 (10.0 – 17.0) 14.0 (8.0 – 18.0)
Difficulties during periodontal therapy† 0.066ns
No 34 (89) 37 (97) 38 (100)
Yes 4 (11) 1 (3) 0 (0)
Discomfort due to periodontal therapy† 0.355ns
No 28 (74) 30 (79) 33 (87)
Yes 10 (26) 8 (21) 5 (13)
Volunteers’ perceptions of the gel's flavor† 0.722ns
Acceptable 28 (74) 26 (69) 27 (71)
Slightly unpleasant 10 (26) 10 (26) 10 (26)
Very unpleasant 0 (0) 2 (5) 0 (0)
I would not like to receive it again 0 (0) 0 (0) 0 (0)
*ANOVA; ‡Kruskal-Wallis; †2 . ns not statistically significant (p≥0.05);
 s statistically significant (p<0.05)
Table 4- Data obtained in trans- and postoperative scaling and root planing in the three intervention groups
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Table 3 presents a comparison of the mean (±SD) 
hemodynamic parameters (secondary outcomes) of 
the different groups. Systolic blood pressure (Sys. 
BP), diastolic blood pressure (Dia. BP) and heart 
rate (HR) were assessed at distinct moments of the 
appointments, i.e., at baseline, during the procedure, 
and after the procedure; oxygen saturation (SpO2) 
was checked at baseline and after treatment. The 
results suggest that this type of intra-pocket anesthetic 
gel for periodontal SRP did not interfere with the 
hemodynamic indices. 
The results showed that the volume of gel applied, 
the number of applications, the need for additional 
(rescue) anesthesia, the time required to perform 
SRP during each session, the difficulties during 
periodontal treatment, and the discomfort caused by 
periodontal therapy were similar between the groups, 
as were the volunteers’ perceptions of the gel’s flavor, 
with no statistically significant differences between 
intervention groups (Table 4).
Discussion
The results of this study did not show statistically 
significant differences between intervention groups 
regarding pain and discomfort; therefore, the null 
hypothesis was accepted. Nevertheless, a recent 
systematic review concluded that topical anesthesia is 
superior to a placebo during probing and SRP because 
it reduces the risk and intensity of pain, as well as the 
need for rescue anesthesia.25 However, there are many 
differences between studies regarding intra-pocket 
anesthesia, such as study design;8,16 composition of 
the anesthetic gel;10,11,26 use of occluded anesthesia;26 
numerically small point estimate differences between 
treatments;27 and type of intervention.14 Most of 
these studies did not consider variables such as the 
influence of acoustic or sound stimuli on the patients’ 
perception of pain, anxiety and fear;5,6 the possible 
discomfort caused by swallowing the gel during the 
procedures;10,28,29 as well as short application time (30 
seconds to 2 minutes),8,11,14,16 removal of the gel during 
scaling and root planing, and dentin hypersensitivity 
during periodontal therapy.2
Our study had a cross-over design: all 38 
volunteers were submitted to SRP using the three 
different gels (placebo and anesthetic) in different 
sextants. Sextant distribution and number of teeth per 
sextant were equivalent between intervention groups. 
The volunteers included in the study had similar 
periodontal parameters between sextants, including 
dental plaque, bleeding on probing, probing depth 
and width of the keratinized mucosa. Conversely, we 
found statistical differences regarding the percentage 
of suppuration. No suppuration sites were observed 
in the Oraqix® group; in contrast, suppuration sites 
were present in 14% of the placebo group and 11% of 
the liposomal gel group. Suppuration was associated 
with higher pain frequency/intensity (NRS-101) 
during scaling and root planning (multilevel regression 
analysis). With regard to the issue of probing depth, 
it was associated with a higher level of pain intensity 
(NRS-101 and VRS-4); our results can be compared 
with those of other studies10,13,14 that had similar 
characteristics such as sample size and study design. 
The association of local anesthetics with liposomal 
formulations increases the duration of anesthesia, 
decreases central nervous and cardiac toxicity, and 
decreases circulating plasma levels.17-19 Liposomal 
topical anesthetics provide a duration of approximately 
10 min of anesthesia in the gingiva and buccal mucosa, 
results similar to those obtained by lidocaine-prilocaine 
cream.21,22 However, other factors could reduce the 
effectiveness of these local anesthetics, such as 
the possibility of removing the gel during scaling 
and root planing while using periodontal curettes 
or sonic/ultrasonic instruments; the presence of 
inflammation in the periodontal pockets, which can 
modify the anesthetics’ pharmacological activity;30 
and the inability of keeping the periodontal pocket 
internally dry due to the continuous plasma transudate 
generated from a gingival trauma caused by scaling 
and root planing.31 In our study, volunteers did not 
report transitory side effects due to the use of different 
topical anesthetics.
This study is the first to evaluate hemodynamic 
parameters (systolic blood pressure, diastolic blood 
pressure, heart rate and oxygen saturation) and 
anxiety during SRP using non-invasive anesthesia. 
No statistically significant differences were found 
between groups, suggesting that lidocaine/prilocaine 
intra-pocket anesthetic gels do not interfere with 
these parameters. Anxiety and fear can have a 
pain-increasing effect, creating an intentional bias 
towards the painful stimuli or pain-related sensation. 
Anxiety-induced somatic changes may occur from 
the activation of the hypothalamus-pituitary-adrenal 
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axis, the main result being increased secretion of 
cortisol. Endogenous or exogenous epinephrine may 
cause or contribute to hemodynamic and cardiac 
changes.32 Dental anxiety may have an impact on 
the effect of local anesthesia, blood pressure, and 
oxygen saturation; it is significantly associated with 
increased heart rate.2,33 Lidocaine-prilocaine cream 
may cause methemoglobinemia and change arterial 
blood saturation and pulse oximetry.34 On the other 
hand, the lidocaine-prilocaine concentration observed 
after the intra-pocket application of Oraqix® was below 
the threshold levels for toxic effect.15 Our study found 
a significant association between dental anxiety and 
pain, indicating that the use of non-invasive anesthesia 
might be a good option for anxious patients who have 
had previous negative experiences with conventional 
anesthesia.35
Some authors have reported that the use of split-
mouth and cross-over designs significantly increased 
efficiency in statistical testing;14,23 however, others 
have argued that a parallel group study design would 
be more appropriate for this type of research in 
order to avoid the possibility of a carry-over or spill-
over effects caused by the volunteers’ perception of 
pain.8,23 Even though a parallel group design might 
contribute to subject blinding,8 it could be influenced 
by factors such as age, gender, ethnicity, previous 
pain experience and education.14 Our results showed 
that around 18% to 39% of the volunteers reported 
severe pain, suggesting that SRP can be a painful 
procedure for some patients. However, such findings 
can be widely divergent because they are influenced by 
factors such as age, type of periodontal therapy, and 
gender.2-4 In similar studies, some patients submitted 
to SRP using a placebo or anesthetic gel asked for 
rescue anesthesia, implying that this type of gel has 
limited applications.8,11,16,36 
In our study, pain and discomfort were assessed 
during/after SRP using pain frequency and two pain-
rating scales: a numerical rating scale (NRS-101) 
and a four-point verbal rating scale (VRS-4). Pain 
frequency provides similar results in comparison to 
the pain scale.3,4 The NRS-101 and VRS-4 scales 
are widely applied due to their validity, reliability 
and sensitivity;37,38 nevertheless, they have some 
limitations linked to the patients’ age and education 
level, as well as to their difficulty expressing pain using 
numbers.39 In other similar studies using non-invasive 
periodontal anesthesia, the most common rating 
scales used were VRS and the visual analogue scale 
(VAS).7-9,11,13,16,26,35 Although the latter is considered 
more sensitive, it has also been claimed that it is not 
as easy to understand as the NRS-101 and VRS-4 
scales, which could lead to higher failure rates.37 It 
is important to note that there is no ideal scale for 
measuring pain and the results need to be carefully 
interpreted by researchers.39
Conclusion
In conclusion, we did not find differences between 
intervention groups in relation to pain frequency/
intensity (primary outcome). The use of intra-pocket 
anesthetic gel for periodontal SRP did not interfere with 
the hemodynamic parameters (secondary outcome). 
Our results suggest limited indications for the use of 
non-invasive periodontal anesthesia: firstly, because 
periodontal procedures usually cause low or moderate 
pain, and secondly, because patients sometimes 
prefer not to receive local anesthesia. Nevertheless, 
some patients may experience severe pain during 
non-surgical periodontal therapy, and conventional 
local anesthesia is often necessary. The use of an 
intra-pocket anesthetic gel could be a good option 
for maintenance patients, anxious patients, or those 
who have a fear of needles. This is the first study 
to evaluate liposomal, thermosetting anesthetic gel 
during SRP. Consequently, further studies should be 
performed to verify its application in dental practice.
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